title: Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.
authors.forename: P
authors.initials: P
authors.lastname: Verschueren
authors.forename: F
authors.initials: F
authors.lastname: Lensen
authors.forename: E
authors.initials: E
authors.lastname: Lerut
authors.forename: K
authors.initials: K
authors.lastname: Claes
authors.forename: R
authors.initials: R
authors.lastname: De Vos
authors.forename: B
authors.initials: B
authors.lastname: Van Damme
authors.forename: R
authors.initials: R
authors.lastname: Westhovens
mesh_terms: D000328:Adult; D000686:Amyloidosis / Q000628:therapy*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D000069285:Infliximab; D008297:Male; D009404:Nephrotic Syndrome / Q000628:therapy*; D025242:Spondylarthropathies / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab